| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
ALLR Stock Overview
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology.
Allarity Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.24 |
| 52 Week High | US$18.20 |
| 52 Week Low | US$1.06 |
| Beta | 0 |
| 1 Month Change | 11.71% |
| 3 Month Change | -24.39% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -88.19% |
Recent News & Updates
Shareholder Returns
| ALLR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 11.7% | -2.0% | 1.1% |
| 1Y | n/a | -23.0% | -9.0% |
Return vs Industry: Insufficient data to determine how ALLR performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how ALLR performed against the US Market.
Price Volatility
| ALLR volatility | |
|---|---|
| ALLR Average Weekly Movement | 20.8% |
| Biotechs Industry Average Movement | 12.3% |
| Market Average Movement | 7.6% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ALLR is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 21% a week.
Volatility Over Time: ALLR's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 13 | James Cullem | https://www.allarity.com |
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.
Allarity Therapeutics, Inc. Fundamentals Summary
| ALLR fundamental statistics | |
|---|---|
| Market Cap | US$12.33m |
| Earnings (TTM) | -US$28.21m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.4x
P/E RatioIs ALLR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALLR income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$28.22m |
| Earnings | -US$28.21m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.84 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 6.0% |
How did ALLR perform over the long term?
See historical performance and comparison